Budesonide treatment had no effect on diABZI‐induced asthma exacerbation, which is characterized by decreased eosinophils (Figure 3B) and conversely increased neutrophils (Figure 3C) associated with higher myeloperoxidase (MPO) (Figure 3D,E) in BALF and lung, dsDNA release in BALF (Figure 3F), CXCL1 in BALF and lung (Figure E6 A,D—Figure S1), CXCL10 and CCL11 in BALF (Figure E6 B,C—Figure S1). Here, CXCL1 is linked to asthma.